Conexiant and Elsevier Announce Licensing Agreement for The Lancet: Research in Context
New specialty-focused initiative connects healthcare professionals with globally authoritative research, advance clinical understanding, and creates trusted engagement opportunities across 10 therapeutic areas TAMPA, Fla. and LONDON, Nov. 9, 2026 /PRNewswire/ -- Conexiant and Elsevier...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 99 stories mentioning NOV, the earliest published 7 Oct 2025.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.